4000 mutated ras gi 6207 cea gi 6301 brachyury infectious disease infectious disease pipeline gs 4774 hbv globeimmune is developing tarmogen product candidates to treat cancer and infectious diseases . tarmogens targeted molecular immunotherapy tarmogens activate the immune system by stimulating a subset of white blood cells called t cells that destroy infected or malignant cells in contrast to traditional vaccines which predominately stimulate antibody production . tarmogens target the molecular profile that distinguishes a diseased cell from a normal cell and are designed to target specific antigens that play a role in oncology indications and infectious diseases . read more fact sheet learn about our tarmogen platform our leading oncology and infectious disease product candidates and our globeimmune management team . download fact sheet all news recent news 07 05 2016 globeimmune announces delisting and deregistration of common stock 05 12 2016 globeimmune announces updates and financial results for first quarter 2016 03 16 2016 globeimmune announces updates and financial results for full year 2015 site map contact us current employees intranet copyright globeimmune inc. all rights reserved . corporate headquarters 1450 infinite drive louisville colorado 80027 phone 303.625.2700 fax 303.625.2710